AstraZeneca CFO Sarin Receives First Performance Share Award Since 2021 Appointment
Dr. Aradhana Sarin's five-year performance share plan award vested on August 17, marking the completion of a three-year performance period and two-year holding requirement.
CFO Award Vests After Five-Year Cycle
AstraZeneca PLC disclosed that Chief Financial Officer Dr. Aradhana Sarin received her first vesting of performance shares since joining the pharmaceutical giant's executive leadership in 2021. The award, granted on August 13, 2021, vested on August 17, 2026, following a five-year cycle that included performance measurement and mandatory holding periods (6-K filing, 2026-08-19).
The award was made under the AstraZeneca Performance Share Plan (AZPSP) and was "subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year period," according to the filing. Following the initial three-year performance period, the award entered a two-year holding period before vesting at the end of that term (6-K filing, 2026-08-19).
Transaction Details
Following the reinvestment of dividends accrued during the performance and holding periods and the withholding of shares to satisfy tax obligations, Dr. Sarin's beneficial interest in ordinary shares changed by 11,133 shares (6-K filing, 2026-08-19). The shares were acquired for nil consideration as part of the compensation structure.
For tax purposes, the fair market value of an ordinary share at vesting was £114.60, representing "the closing price on the last trading day preceding the vesting" (6-K filing, 2026-08-19). The transaction was conducted outside a trading venue on August 17, 2026.
Regulatory Disclosure
The filing was made in accordance with the EU Market Abuse Regulation as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018. The disclosure identifies Dr. Sarin as an Executive Director and Chief Financial Officer, with the transaction involving ordinary shares of $0.25 each in AstraZeneca PLC (6-K filing, 2026-08-19).
The 6-K filing was signed by Company Secretary Matthew Bowden on August 19, 2026, pursuant to the requirements of the Securities Exchange Act of 1934 (6-K filing, 2026-08-19).
Company Context
AstraZeneca, headquartered in Cambridge, UK, is a global biopharmaceutical company focused on prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology (6-K filing, 2026-08-19). The company's medicines are sold in more than 125 countries.
According to MarginX data, AstraZeneca is scheduled to present at the Handelsbanken Life Science Innovation Day on August 25, 2026, and the Jefferies Swiss Healthcare Summit on September 2, 2026. The company trades on the London Stock Exchange, Stockholm Stock Exchange, and New York Stock Exchange under the ticker AZN, with a market capitalization of approximately $253 billion and a last close of $120.50.
MarginX data also indicates recent insider activity involving Mani Sharma, with an award of 2 shares.
This article was generated by MarginX from the 6-K filing on 2026-08-19. It is not investment advice.